Argus analyst Joseph Bonner kept his Buy rating and $156 price target on Splunk, saying the concerns among investors about the company's operating cash flow guidance that drove yesterday's 7.8% decline in the stock price may be a "timing issue" reflecting its shift to a "ratable sales model". The analyst expects the company to remain supported by its strong revenue growth within a rapidly expanding big data analytics market, raising his FY20 and FY21 EPS forecasts by 8c and 4c to $1.93 and $2.35 respectively. Bonner also believes that Splunk may attract takeover interest from a larger enterprise software company.

New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).